The deal, announced on June 30, will advance a subsect of research into new autoimmune treatments that began at Penn.

AbbVie ABBV has been expanding its oncology portfolio over the past few years. While the company was originally focused on two blood-cancer drugs — Imbruvica and Venclexta — it has since built a ...

Elon Musk’s iconic electric vehicle brand Tesla on Tuesday formally made its entry into the Indian market with its first ...

AbbVie has acquired global rights to the lead pipeline asset of Ichnos Glenmark Innovation (IGI), the cancer and autoimmune disease candidate ISB 2001, through an exclusive licensing agreement that ...

AbbVie Inc. (NYSE:ABBV) is one of Goldman Sachs’ top healthcare stock picks. On July 10, the stock jumped 3.4% on the ...

There’s really no such thing as a “no brainer” stock pick. I’d say that some opportunities are more compelling than others.

The global Botulinum Toxins Market, valued at US$8.1 billion in 2024 stood at US$8.9 billion in 2025 and is projected to ...

Glenmark Pharmaceuticals shares rallied 10% on Friday to reach a record high after its biotech subsidiary signed a ...

AbbVie Inc. (NYSE:ABBV) is one of the best high growth stocks. On June 30, Morgan Stanley maintained an Overweight rating and ...

AbbVie ABBV has successfully navigated the loss of exclusivity (LOE) for its flagship drug, Humira, by launching two newer ...

The global biologics market is estimated to be valued at USD 450.2 billion in 2025 and is projected to reach USD 1,077.2 billion by 2035, registering a CAGR of 9.1% over the forecast period. The ...